At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Mar 11, 2026 at 07:00 ET
Arvinas announced that Phase 1 clinical trial data for its investigational Parkinson’s disease drug ARV-102 will be presented at the AD/PD™ 2026 conference. The data will include safety, pharmacokinetic, and pharmacodynamic results from multiple doses in Parkinson’s patients, with a planned Phase 1b trial in progressive supranuclear palsy (PSP) pending regulatory feedback.
- ARV-102 is an oral PROTAC degrader targeting LRRK2, designed to cross the blood-brain barrier.
- Phase 1 data on safety, PK, and PD will be presented at AD/PD™ 2026 on March 18, 2026.
- Arvinas plans to initiate a Phase 1b trial in PSP patients in the first half of 2026, pending regulatory feedback.
- No efficacy data or clinical outcomes were disclosed, only safety and pharmacological profiles.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access